Immunovant, Inc.
IMVTNASDAQHealthcare● Active
$30.80
$-0.31(-1.00%)
Market Cap$6.3B
P/E Ratio—
52W High$36.285
52W Low$14.32
Immunovant, Inc.（IMVT）· 资产负债表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · IMVT · 截至 2026-06-10
财务报表
Total Assets · Total Liabilities · Equity
| Breakdown | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & ST Investments | $0.90B | $0.71B | $0.64B | $0.38B | $0.49B |
| Net Receivables | $0.00B | $0.00B | $0.01B | $0.00B | $0.01B |
| Inventory | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Current Assets | $0.95B | $0.77B | $0.67B | $0.40B | $0.51B |
| PP&E Net | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Goodwill | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Intangible Assets | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Assets | $0.96B | $0.78B | $0.67B | $0.41B | $0.52B |
| Liabilities | |||||
| Short-Term Debt | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Accounts Payable | $0.01B | $0.02B | $0.01B | $0.00B | $0.02B |
| Total Current Liabilities | $0.10B | $0.07B | $0.05B | $0.04B | $0.04B |
| Long-Term Debt | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Liabilities | $0.10B | $0.07B | $0.05B | $0.04B | $0.05B |
| Stockholders Equity | |||||
| Retained Earnings | ($1.75B) | ($1.24B) | ($0.83B) | ($0.57B) | ($0.36B) |
| Total Stockholders Equity | $0.85B | $0.71B | $0.62B | $0.36B | $0.47B |
| Total Liab & Equity(computed) | $0.96B | $0.78B | $0.67B | $0.41B | $0.52B |
| Debt Summary | |||||
| Total Debt | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Debt | ($0.90B) | ($0.71B) | ($0.64B) | ($0.38B) | ($0.49B) |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Immunovant, Inc.
关于Immunovant, Inc.（IMVT）资产负债表
Immunovant, Inc.总资产$0.96B，现金及短期投资$0.90B，总负债$0.10B，总债务$0.00B，股东权益$0.85B。
常见问题
IMVT · 4 问Immunovant, Inc.总债务$0.00B，净债务($0.90B)。
IMVT total debtnet debtdebt to equity
· Source: FMP /stable/balance-sheet-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10